Best Practice & Research Clinical Haematology
Volume 20, Issue 1 , Pages 91-97 , March 2007

Novel strategies for the treatment and diagnosis of graft-versus-host-disease

  • James L.M. Ferrara, MD (Director, University of Michigan Blood and Marrow Transplant Program)

      Affiliations

    • Corresponding Author InformationTel.: +1 734 615 1340; Fax: +1 734 647 9271.

References 

  1. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295–304
  2. Murphy GF, Korngold R. Significance of selectively targeted apoptotic rete cells in graft-versus-host disease. Biology of Blood and Marrow Transplantation. 2004;10:357–365
  3. Yanik G, Cooke KR. The lung as a target organ of graft-versus-host disease. Seminars in Hematology. 2006;43:42–52
  4. Perrotta PL, Snyder EL. Non-infectious complications of transfusion therapy. Blood Reviews. 2001;15:69–83
  5. Abo-Zena RA, Horwitz ME. Immunomodulation in stem-cell transplantation. Current Opinion in Pharmacology. 2002;2:452–457
  6. Weisdorf DJ. Phase II randomized study of etanercept versus mycophenolate mofetil versus denileukin diftitox versus pentostatin in combination with prednisone or methylprednisolone in patients with acute graft-versus-host disease who have undergone a prior allogeneic hematopoietic stem cell transplant. http://www.clinicaltrials.gov/ct/show/NCT00253656?order=12006;
  7. Goker H, Haznedaroglu IC, Chao NJ. Acute graft-vs-host disease: pathobiology and management. Experimental Hematology. 2001;29:259–277
  8. Ferrara JL, Reddy P. Pathophysiology of graft-versus-host disease. Seminars in Hematology. 2006;43:3–10
  9. Simpson E. Minor transplantation antigens: animal models for human host-versus-graft, graft-versus-host, and graft-versus-leukemia reactions. Transplantation. 1998;65:611–616
  10. Teshima T, Ordemann R, Reddy P, et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nature Medicine. 2002;8:575–581
  11. Korngold R, Marini JC, de Baca ME, et al. Role of tumor necrosis factor-alpha in graft-versus-host disease and graft-versus-leukemia responses. Biology of Blood and Marrow Transplantation. 2003;9:292–303
  12. Ferrara JL, Levy R, Chao NJ. Pathophysiologic mechanisms of acute graft-vs.-host disease. Biology of Blood and Marrow Transplantation. 1999;5:347–356
  13. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood. 2000;95:2754–2759
  14. Cooke KR, Hill GR, Crawford JM, et al. Tumor necrosis factor- alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. The Journal of Clinical Investigation. 1998;102:1882–1891
  15. Yanik GA, Uberti JP, Ferrara JLM, et al. Etanercept for sub-acute lung injury following allogeneic stem cell transplantation. Blood. 2003;102:471a;(abstract)
  16. Uberti JP, Ayash L, Ratanatharathorn V, et al. Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. Biology of Blood and Marrow Transplantation. 2005;11:680–687
  17. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356:385–390
  18. Chiang KY, Abhyankar S, Bridges K, et al. Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease. Transplantation. 2002;73:665–667
  19. Hill GR, Crawford JM, Cooke KR, et al. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood. 1997;90:3204–3213
  20. Baker KS, Allen RD, Roths JB, et al. Kinetic and organ-specific patterns of cytokine expression in acute graft-versus-host disease. Bone Marrow Transplantation. 1995;15:595–603
  21. Levine JE, Yanik GA, Cooke KR, et al. Elevated TNF receptor levels early after myeloablative BMT predict for GVHD and death. Biology of Blood and Marrow Transplantation. 2006;12;(abstract 138)

PII: S1521-6926(06)00084-3

doi: 10.1016/j.beha.2006.11.004

Best Practice & Research Clinical Haematology
Volume 20, Issue 1 , Pages 91-97 , March 2007

Article Tools

* Image Usage & Resolution